glp 1 medications The GLP-1 revolution: What UAB researchers are discovering about how these drugs work The GLP-1 revolution: What UAB

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Effectiveness and Impact Significant Weight Loss: Phase 2 studies showed up to roughly 20% average body weight loss at 52 weeks in participants with obesity

This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.

GLP-1 medications such as Ozempic and Wegovy have significantly reshaped the weight loss market by improving blood sugar regulation, insulin sensitivity, and appetite control

Curious about Microdosing GLP-1

Gastrointestinal symptoms such as nausea, constipation, and indigestion are most common and usually subside as your body adjusts